Loading…
← CockpitCompetitor Analysis › MLAB Mesa Laboratories, Inc.Open in the cockpit ↗

Mesa Laboratories, Inc.MLABCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 90
Mkt cap
$775M
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$14.3M
20-day average traded
Fwd P/E
11.5×
forward earnings
ROIC−WACC
-3.2 pp
WACC 9.7%
Hurdle
+8 pp
Req g minus delivered
Next earnings
82 days
8 Feb 2027
Close · USD$137.81
1D+2.4%
1W-1.0%
1M+10.1%
3M+15.7%
6M+32.5%
YTD+75.5%
1Y+92.4%
ATR %4.2%
Beta1.18
52w lowhigh4.5% off high

What Mesa Laboratories does

Employees: 717

Mesa Laboratories at a glance

Size Mesa Laboratories (MLAB) is a United States Health Care company (Medical Specialties) with a market value of $775M, the 2391st largest of 3,085 United States companies the cockpit tracks. Shares closed at $137.81 on 18 Nov 2026.

Performance Over six months the shares gained 32.5%, against -17.5% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 2.5% over the last twelve months (peer median +12.6%); the operating margin is 10.4% (peer median 12.8%).

Valuation It trades at 11.5× forward earnings against a peer median of 20.0× (2nd cheapest of 14).

Price implies For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.2 points below its cost of capital (9.7% WACC).

Short interest Short interest is 6.7% of the free float (30 Oct 2026).

Next results Next results expected around 8 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026MLAB 126Peer median 84
Six months, rebased to 100: Mesa Laboratories against the median of its 20 peers (local-currency closes).

Mesa Laboratories financials

Reported figures in USD; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$251M$249M$241M$216M$219M
Revenue growth—+3%+11%-1%—
Gross profit$146M$141M$132M$111M$111M
EBITDA$48.8M$41.8M$40.9M$36.3M$36.5M
Net income$6.67M$6.71M-$1.97M-$254M$930,000
Free cash flow$49.5M$39.6M$42.6M$41.6M$23.4M
Capital expenditure$2.10M$3.25M$4.50M$2.57M$4.54M
Total debt$150M$169M$194M$231M$192M

Quarterly statements and history in the cockpit →

Mesa Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%-10%0%+10%CTKB1302VREXBBNX2190SETL300463688108002950300453603108096530AMSMCAP301367688068688805MLAB6-month return →1-month return →
Up and to the right = strong over both horizons. Mesa Laboratories is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×1302VREX2190300463688108300453603108096530AMS301367MLABRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Mesa Laboratories is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%13022190300463688108300453603108096530INMDAMS688805MLABGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Mesa Laboratories is the large dot.

Mesa Laboratories competitors and peer comparison

How Mesa Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Mesa Laboratories against its 20 peers (data as of 18 Nov 2026)
MeasureMLABPeer medianRank in peer set
1-month return+10.1%-8.5%2nd highest of 21
6-month return+32.5%-17.5%5th highest of 21
Distance from 52-week high-4.5%-41.0%3rd highest of 21
Revenue growth (TTM)+2.5%+12.6%5th lowest of 21
Operating margin10.4%12.8%9th lowest of 21
Forward P/E11.5×20.0×2nd cheapest of 14
Growth the price implies (Req g, 7 yrs)21.3%7.9%3rd most demanding of 14
Growth delivered (Del g)+13.2%+15.5%7th lowest of 14
Hurdle (Req g minus delivered)+8.0 pp-5.9 pp6th most demanding of 14
ROIC minus cost of capital-3.2 pp-0.3 pp8th lowest of 21
EV / EBITDA18.5×13.1×2nd most expensive of 9
Net debt / EBITDA2.6×-1.5×2nd most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Mesa Laboratories MLABUnited States$775M+33%+2%10%11.5×21.3%+13.2%
Cytek Biosciences CTKBUnited States$774M+57%+6%-21%n/an/an/a
LifeTech Scientific 1302.HKHong Kong$771M-30%+1%12%19.8×9.6%+15.5%
Varex Imaging VREXUnited States$771M+79%+5%8%19.9×n/an/a
Beta Bionics BBNXUnited States$779M+42%+44%-73%n/an/an/a
Zylox-Tonbridge Medical Technology 2190.HKHong Kong$768M-16%+39%25%14.4×3.8%+105.8%
Standard Engineering Technology SETL.NSIndia$783M+168%+45%14%n/an/an/a
Maccura Biotechnology 300463.SZChina$756M-18%-1%-4%421.0×7.9%-10.2%
Sino Medical Sciences Technology 688108.SSChina$753M-41%+22%19%60.0×27.9%+9.9%
Allmed Medical Products 002950.SZChina$747M-32%+14%8%n/an/an/a
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%16.2×-1.9%+11.8%
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%20.5×20.3%-0.2%
Seegene 096530.KSSouth Korea$808M-26%+13%13%20.0×-6.7%-15.9%
InMode INMDUnited States$741M-8%+2%18%9.8×-10.8%+12.4%
Advanced Medical Solutions AMS.LUnited Kingdom$811M+27%+6%12%20.7×20.0%+21.4%
MedCap MCAP.STSweden$811M-4%+17%15%25.8×2.7%+20.9%
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%n/an/an/a
BMC Medical 301367.SZChina$737M-17%+37%17%18.7×-1.5%+15.6%
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%n/an/an/a
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%27.4×17.1%+24.2%
Ningbo Jansen Superconducting Technologies 688805.SSChina$818M-36%+36%16%n/a35.6%+17.1%

Questions

Which companies are Mesa Laboratories's closest peers?
The cockpit's peer set: Cytek Biosciences (CTKB), LifeTech Scientific (1302.HK), Varex Imaging (VREX), Beta Bionics (BBNX), Zylox-Tonbridge Medical Technology (2190.HK), Standard Engineering Technology (SETL.NS), Maccura Biotechnology (300463.SZ), Sino Medical Sciences Technology (688108.SS).
Is Mesa Laboratories expensive compared with its peers?
On forward p/e it trades at 11.5× against a peer median of 20.0×, 2nd cheapest of 14 in its peer set. For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Mesa Laboratories stock performed?
Over six months to 18 Nov 2026 the shares returned +32.5% against -17.5% for the median peer; over one year +92.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.